Market Place
Sourcing Support
Seagen’s former commercial chief joins the board at healthcare agency
22 Mar 2024 //
ENDPTS
TUKYSA® Improves Progression-Free Survival in Patients with Breast Cancer
06 Dec 2023 //
BUSINESSWIRE
Overall survival data blur Seagen`s Tukysa-ADC path
06 Dec 2023 //
FIERCE PHARMA
Seagen`s breast cancer drug Tukysa boosts Roche`s ADC
17 Aug 2023 //
FIERCE PHARMA
Seagen says Tukysa combo hits main goal in Phase III breast cancer study
17 Aug 2023 //
BUSINESSWIRE
Seagen Announces FDA Accelerated Approval of TUKYSA with Trastuzumab
19 Jan 2023 //
BUSINESSWIRE
Seagen secures FDA review on Tukysa as Merck buyout talks reportedly stall
20 Sep 2022 //
ENDPTS
Seagen to Highlight Research in Urothelial & Colorectal Cancers at ESMO Congress
07 Sep 2022 //
BUSINESSWIRE
Seagen Announces Results from Pivotal MOUNTAINEER Trial in TUKYSA
02 Jul 2022 //
BUSINESSWIRE
Seagen`s Tukysa shows promise in colorectal cancer
24 May 2022 //
FIERCEPHARMA
South Korea approves PIII trials of breast cancer treatment `Tucatinib`
19 Apr 2022 //
ET HEALTH
NICE draft guidance recommends tucatinib for advanced breast cancer
25 Feb 2022 //
PHARMAFILE
Seagen Reports Fourth Quarter and Full Year 2021 Financial Results
09 Feb 2022 //
BUSINESSWIRE
Pieris Pharma Announces First Patient Dosed Phase 2 Gastric Cancer
14 Jan 2022 //
TRIALSITENEWS
Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA
08 Dec 2021 //
BUSINESSWIRE
Seagen to Highlight New Data in Advanced Breast Cancer at 2021 SABCS
19 Nov 2021 //
BUSINESSWIRE
Seagen Reports Third Quarter 2021 Financial Results
28 Oct 2021 //
BUSINESSWIRE
NICE does not recommend tucatinib in new draft guidance
26 Oct 2021 //
EUROPEANPHARMACEUTICALREVIEW
Seagen Completes Enrollment in Phase 2, TUKYSA Regimen in HER2-Positive mCRC
28 Sep 2021 //
BUSINESSWIRE
Seagen Announces Long-Term Results from TUKYSA® (tucatinib)
03 Jun 2021 //
BIOSPACE
MHRA approves Seagen’s Tukysa for HER2-positive breast cancer
23 Feb 2021 //
PHARMAATIMES
EU approves Tukysa combo for advanced HER2-positive breast cancer
17 Feb 2021 //
PHARMATIMES
Tucatinib Approved in Europe for Locally Advanced or Metastatic HER2+ Breast
12 Feb 2021 //
PRESS RELEASE
Seagen Announces Positive CHMP Opinion for TUKYSA® (tucatinib)
11 Dec 2020 //
BUSINESSWIRE
Seagen Announces Positive CHMP Opinion for TUKYSA® (tucatinib)
11 Dec 2020 //
BUSINESSWIRE
Seagen Highlights TUKYSA® (tucatinib) Data in Breast Cancer at Virtual 2020
08 Dec 2020 //
BUSINESSWIRE
Seagen Reports Third Quarter 2020 Financial Results
30 Oct 2020 //
BUSINESSWIRE
Merck Announces Two Oncology Collaborations with Seattle Genetics
16 Sep 2020 //
PHARMTECH
Seattle Genetics Announces TUKYSA® (tucatinib) Approved Within Months
11 Aug 2020 //
BUSINESSWIRE
Seattle Genetics Announces Positive Results HER2CLIMB for TUKYSA™ (tucatinib)
29 May 2020 //
PRESS RELEASE
Seattle Genetics Announces the Approval of TUKYSA™ (tucatinib) in Switzerland
12 May 2020 //
BUSINESSWIRE
TUKYSA™ (tucatinib) Approved for the Treatment of Human Epidermal Growth
20 Apr 2020 //
BUSINESSWIRE
Seattle Genetics breaks into breast cancer with new approval Tukysa
18 Apr 2020 //
FIERCE PHARMA
FDA approves first new drug under Project Orbis
17 Apr 2020 //
RAPS
Seattle Genetics gets another drug close to the finish line
13 Feb 2020 //
ENDPTS
Seattle Genetics nabs FDA breakthrough tag for tucatinib
18 Dec 2019 //
FIERCE BIOTECH
Seattle Genetics hails `stunning` tucatinib breast cancer data
12 Dec 2019 //
FIERCE BIOTECH
SeaGen to Seek FDA Nod After Breast Cancer Drug Hits Goals of Key Study
22 Oct 2019 //
XCONOMY
Seattle Genetics Announces +ve Topline Results from Pivotal Trial of Tucatinib
21 Oct 2019 //
BUSINESSWIRE
Seattle Genetics` breast cancer drug hits mark in pivotal trial
21 Oct 2019 //
FIERCE BIOTECH
Seattle Genetics makes case it can be more than Adcetris
30 Sep 2019 //
BIOPHARMADIVE
